Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 12/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 11/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 11/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28210517 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL21581280 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL21581261 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL18761564 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL18612783 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL369682 | 0.98 | GNAO1 (0.43) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL22702328 | 0.96 | GNAO1 (0.42) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL22702329 | 0.94 | SIGMAR1 (0.42) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL18699333 | 0.93 | SIGMAR1 (0.41) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL30859683 | 0.93 | SIGMAR1 (0.41) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-20220213109-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| US-11161847-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-11-02 | — | — | US | disclosed |
| US-20200155540-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155540-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | GNAO1 2648/4885GNAI3 1296/4885GNAI1 1951/4885 |
| US-11161847-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | GNAO1 1057/4885GNAI3 64/4885GNAI1 40/4885 |
| US-20220213109-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | GNAO1 1139/4885GNAI3 69/4885GNAI1 37/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | GNAO1 258/4885GNAI3 38/4885GNAI1 34/4885 |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDXK, CMPK1, GCK | GNAO1 2286/4885GNAI3 2144/4885GNAI1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.